Physician profile
Azeb Telahun
NPI 1487746228
$4,116.88
in general payments reported to CMS, 2019-2025
25 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $467 · 2021: $378 · 2022: $1,046 · 2023: $266 · 2024: $1,038 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777 · Education: $2.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.98 |
| Education | $2.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.63 | 2022-2025 | Ozurdex, Durysta |
| Alcon Vision LLC | $441.65 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Bausch & Lomb Americas INC. | $371.53 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Kala Pharmaceuticals, INC. | $354.05 | 2019-2022 | |
| Allergan, INC. | $351.02 | 2019-2022 | |
| Sight Sciences, INC. | $347.55 | 2020-2025 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $329.87 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $236.07 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $213.43 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $196.06 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $156.80 | 2019-2021 | |
| Horizon Therapeutics Plc | $149.66 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $144.46 | 2019 | |
| Eyevance Pharmaceuticals LLC | $84.52 | 2021-2022 | |
| Harrow Eye, LLC | $52.99 | 2024-2025 | Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.71 | 2024-2025 | Tepezza |
| Rxsight INC | $30.37 | 2022 | |
| Dompe US, INC. | $25.30 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $20.98 | 2019 | |
| New World Medical,INC. | $20.91 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Glaukos Corporation | $16.25 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Rayner Intraocular Lenses Limited | $15.63 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Aspheric |
| Shire North American Group INC | $12.60 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azeb Telahun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.